Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600508 | 0.84 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL9667165 | 0.80 | RAB9A (0.68) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3429462 | 0.80 | SMN1; SMN2 (1.00) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL9665950 | 0.80 | RAB9A (0.63) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3079520 | 0.79 | SMN1; SMN2 (0.83) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3065316 | 0.79 | SMN1; SMN2 (0.69) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL21777592 | 0.79 | RAB9A (0.76) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3789333 | 0.79 | SMN1; SMN2 (1.00) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL26762334 | 0.77 | RAB9A (0.59) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 | |
| SCHEMBL11130494 | 0.76 | NPC1 (0.65) | NPC1RAB9ALMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0234980-B1 | 2-BENZIMIDAZOLYLALKYLTHIO (OR SULFINYL OR SULFONYL) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1992-09-16 | — | — | EP | claimed |
| EP-0234980-A1 | 2-Benzimidazolylalkylthio (or sulfinyl or sulfonyl) derivatives, their preparation and their use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1987-09-02 | — | — | EP | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0234980-B1 | 2-BENZIMIDAZOLYLALKYLTHIO (OR SULFINYL OR SULFONYL) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1992-09-16 | — | — | EP | disclosed |
| US-4791114-A | GASTROINTESTINAL DISORDERS; ANTISECRETORY AGENTS; CYTOPROTECTIVE AGENTS | 501 Laboratorios Del, Dr. Esteve (ES) | 1988-12-13 | — | — | US | disclosed |
| EP-0234980-A1 | 2-Benzimidazolylalkylthio (or sulfinyl or sulfonyl) derivatives, their preparation and their use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | NPC1 363/4885RAB9A 486/4885LMNA 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.